Articles by James Calloway
Transocean Shares Drop 9% Despite $1.6B in New Contracts
Transocean shares fell 9.16% after reporting an adjusted Q1 loss of $28 million, despite $1.6 billion in new contracts. The DOJ's second request for the Valaris deal adds regulatory uncertainty.
Upstart Stock Plunges 14% as Profit Margins Disappoint Despite Surging Loan Volume
Upstart shares tumbled 13.9% after hours as the AI lender's wider net loss and lower adjusted EBITDA overshadowed a 44% revenue surge and robust loan growth.
Occidental Petroleum Q1 Profit Tops Estimates, Debt Reduction in Focus
Occidental Petroleum reported Q1 adjusted EPS of $1.06, above expectations, as US production rose. The company reduced debt to $13.3 billion and lowered its full-year production forecast. CEO transition planned for June 1.
Klaviyo Beats Q1 Estimates, CFO Departure Weighs on Shares
Klaviyo shares dropped 19% in after-hours trading despite beating Q1 estimates, as CFO Amanda Whalen's planned exit overshadowed strong results and a raised 2026 outlook.
AMC Revenue Surpasses $1 Billion in Q1, but Debt Challenges Linger
AMC Entertainment's Q1 revenue topped $1 billion, beating analyst estimates, but the company remains burdened by substantial debt and negative free cash flow.
FINRA Probes Morgan Stanley's Budapest Analyst Program Over Licensing
FINRA is investigating Morgan Stanley's Budapest analyst program after a whistleblower alleged unlicensed work on US and European deals and client data mishandling.
Astera Labs Surges on AI Revenue Beat, Switch Debut Next
Astera Labs beat Q1 estimates with revenue up 93% to $308.4M and issued strong Q2 guidance. Shares rose 1.27% after hours as the company begins shipping its Scorpio X-Series AI switch.
Arista Networks Stock Tumbles Despite Strong Q1 as AI Guidance Fails to Impress
Arista Networks beat Q1 earnings estimates but saw shares drop 5.8% after hours as Q2 guidance met, not exceeded, expectations and gross margin fell.
Cellectar Biosciences Secures $140M, Pushes Iopofosine Toward FDA Filing
Cellectar Biosciences secured up to $140 million in new funding and reported strong Phase 2b results for iopofosine, fueling plans for a confirmatory trial and FDA filing in Waldenström macroglobulinemia.
Backblaze Surges on AI Demand, Lifts 2026 Forecast
Backblaze shares soared Tuesday after the company raised its 2026 outlook, citing strong AI demand for its B2 Cloud Storage platform.